Abstract
Characterization of liver-specific autoantigens has given a fresh impetus to research in the pathogenesis of autoimmune liver diseases, viral-triggered and drug-induced autoimmunity affecting the liver. Intriguing is the fact that most of the liver-specific autoantigens are enzymes of key importance for cells homeostasis. Detection of autoantibodies against the respective antigens is carried out for diagnostic and research purposes using indirect immunofluorescence, immunoblotting, enzyme-linked immunosorbent assays, radioimmunoassay, immunoprecipitation or assays determining inhibition of enzyme activity. In patients with autoimmune hepatitis, a liver disorder of unknown etiology and pathogenesis, disease-specific autoantibodies are frequently directed against drug metabolizing enzymes of phase 1, namely cytochrome P450 2D6 (CYP2D6). The same and other members of these families of enzymes (CYPs) have also been described as targets of liver-specific autoimmunity in chronic hepatitis C virus (HCV)-infected patients, patients with autoimmune hepatitis as part of the autoimmune polyglandular syndrome type-1 (APS-1) and drug-induced autoimmunity. How these enzymes become ‘self targets’ is not yet established. An antigen release following hepatocyte injury could provide the stimulus for an immune response towards epitopes on these enzymes but the highly-specific, antigenrestricted initiation of the observed autoimmune response is against such an explanation. Accordingly, in this review we will focus on the pathogenic role -if any- of autoimmune responses against liver-related CYPs in autoimmune hepatitis, HCV infection, APS-1 and drug-induced autoimmunity. Learning more about the specificity of antibody responses against these enzymes may help us better understand the mechanisms underlying liver autoimmunity and may facilitate the development of therapeutic and preventive interventions.
Keywords: Autoimmune hepatitis, cytochrome P4502D6, cytochrome P4502A6, cytochrome P4501A2, autoimmune polyglandular syndrome type 1, drug induced hepatitis, hepatitis C virus, antibodies to liver kidney microsomal antigens (anti-LKM)
Current Medicinal Chemistry
Title: Enzymes as Target Antigens of Liver-Specific Autoimmunity: The Case of Cytochromes P450s
Volume: 15 Issue: 22
Author(s): D. P. Bogdanos and G. N. Dalekos
Affiliation:
Keywords: Autoimmune hepatitis, cytochrome P4502D6, cytochrome P4502A6, cytochrome P4501A2, autoimmune polyglandular syndrome type 1, drug induced hepatitis, hepatitis C virus, antibodies to liver kidney microsomal antigens (anti-LKM)
Abstract: Characterization of liver-specific autoantigens has given a fresh impetus to research in the pathogenesis of autoimmune liver diseases, viral-triggered and drug-induced autoimmunity affecting the liver. Intriguing is the fact that most of the liver-specific autoantigens are enzymes of key importance for cells homeostasis. Detection of autoantibodies against the respective antigens is carried out for diagnostic and research purposes using indirect immunofluorescence, immunoblotting, enzyme-linked immunosorbent assays, radioimmunoassay, immunoprecipitation or assays determining inhibition of enzyme activity. In patients with autoimmune hepatitis, a liver disorder of unknown etiology and pathogenesis, disease-specific autoantibodies are frequently directed against drug metabolizing enzymes of phase 1, namely cytochrome P450 2D6 (CYP2D6). The same and other members of these families of enzymes (CYPs) have also been described as targets of liver-specific autoimmunity in chronic hepatitis C virus (HCV)-infected patients, patients with autoimmune hepatitis as part of the autoimmune polyglandular syndrome type-1 (APS-1) and drug-induced autoimmunity. How these enzymes become ‘self targets’ is not yet established. An antigen release following hepatocyte injury could provide the stimulus for an immune response towards epitopes on these enzymes but the highly-specific, antigenrestricted initiation of the observed autoimmune response is against such an explanation. Accordingly, in this review we will focus on the pathogenic role -if any- of autoimmune responses against liver-related CYPs in autoimmune hepatitis, HCV infection, APS-1 and drug-induced autoimmunity. Learning more about the specificity of antibody responses against these enzymes may help us better understand the mechanisms underlying liver autoimmunity and may facilitate the development of therapeutic and preventive interventions.
Export Options
About this article
Cite this article as:
Bogdanos P. D. and Dalekos N. G., Enzymes as Target Antigens of Liver-Specific Autoimmunity: The Case of Cytochromes P450s, Current Medicinal Chemistry 2008; 15 (22) . https://dx.doi.org/10.2174/092986708785747508
DOI https://dx.doi.org/10.2174/092986708785747508 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Chemo-botanical and Neurological Accounts of Some Ayurvedic Plants Useful in Mental Health
The Natural Products Journal Design, Synthesis, and Screening of Hybrid Benzothiazolyl-Oxadiazoles as Anticonvulsant Agents
Letters in Drug Design & Discovery Patent Selections
Recent Patents on Computer Science Pharmacological Effects and Chemical Constituents of Bupleurum
Mini-Reviews in Medicinal Chemistry The Genetic Components of Alcohol and Nicotine Co-Addiction: From Genes to Behavior
Current Drug Abuse Reviews Gastrin-Releasing Peptide Receptor as a Molecular Target for Psychiatric and Neurological Disorders
CNS & Neurological Disorders - Drug Targets Editorial [Hot Topic: Therapeutic Potential of Peptide Motifs - Part I (Executive Editor: Jean-Claude Herve)]
Current Pharmaceutical Design Herbal Medicine in the Treatment of Epilepsy
Current Drug Targets Recent Multiple Transition Metal Catalysed Single-Pot Reactions
Current Organic Synthesis Nutritional and Pharmacological Management of Childhood Epilepsy: Ketogenic Diets and Common AEDs
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Biological Drugs in Guillain-Barré Syndrome: An Update
Current Neuropharmacology Hepatoprotective Effects and Antioxidant Potential of Polyherbal Formulation Against CCl4- Induced Hepatic Injury in Albino Rats
Current Traditional Medicine Synthesis and Biological Evaluation of New 4-Thiazolidinone Derivatives as Carbonic Anhydrase Inhibitors
Letters in Organic Chemistry Cytochrome P450 in Neurological Disease
Current Drug Metabolism Poor Safety and Tolerability Hamper Reaching a Potentially Therapeutic Dose in the Use of Thalidomide for Alzheimer’s Disease: Results from a Double-Blind, Placebo-Controlled Trial
Current Alzheimer Research The Quest for Eldorado: Development of Radioligands for In Vivo Imaging of Nicotinic Acetylcholine Receptors in Human Brain
Current Pharmaceutical Design 123I-FP-CIT Brain SPECT Findings in Succinic Semialdehyde Dehydrogenase (SSADH) Deficiency
Current Radiopharmaceuticals Carbohydrate-Based Drugs in the Treatment of Epilepsy, Depression and Other Affective Disorders
Current Topics in Medicinal Chemistry Clonal Expansion of Mitochondrial DNA Deletions and the Progression of Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets Synthesis and Evaluation of the Anticonvulsant Activity of 5-alkylthio-4- phenyl-2,4-dihydro-3H-1,2,4-triazol-3-one Derivatives
Letters in Drug Design & Discovery